MedTrace Logo

Topical IL-1-Ra for Treatment of Posterior Blepharitis

NCT00681109 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2018-01-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness and safety of Topical Interleukin-1-Receptor Antagonist in treatment of signs and symptoms of posterior blepharitis.

Conditions

  • Posterior Blepharitis

Interventions

DRUG

2.5% IL-1Ra

2.5% custom made topical IL-1Ra three times a day in both eyes for three months

DRUG

Placebo

custom eye drop to be applied three times a day in both eyes for three months

DRUG

5% IL-1Ra

5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months

Sponsors & Collaborators

  • Reza Dana, MD

    lead OTHER

Principal Investigators

  • Reza Dana, MD, MPH, MSc · Massachusetts Eye and Ear Infirmary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-05-31
Completion
2010-10-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00681109 on ClinicalTrials.gov